I think you missed a bunch of questions and requests for links to the "Facts" that have not turned out to be facts

I agree

They all own shares, some own or have access to a ton. I think it may happen when the time is right. These guys can all make Elite very profitable, control their stock price however they wish the old fashion way....revenue and products.

Then when it is where they want it they can sell the company, or sell their shares. There has been speculation that Actavis owns Epic and there is smoke there as well

That is a great question isn't it. Also have you seen the lack of volume even now during these trading days? When the preferreds converted and sold off, those shares were gobbled up. 10s of millions of shares.

Note the consistent barage of posters on various message boards that have the clear intent to create doubt, disillusion people, create false premises that can not be back up with data, links, honest DD, logic or through lies of ommission.

I've doubted but then I go through everything I know about the company and it makes no sense whatsoever. I have learned to not follow sheep, trust the data, trust myself.

Stating that links have been posted and actually do so are two different things.

Please note the discussion from post 11134 through 11278. Again, numerous requests for data to back up claims, items identified as "facts" but without links and then refuted with actual links and still no response.

It is obvious that the "facts" are incorrect and the links to back them up do not exist. Do you agree with that statement at this point considering the numerous requests for this data?

That didn't answer the question. As usual and noted multiple times, seems the so called "facts" are again lacking.

Here is the question again

Patent from 2004, yet where are the products? Multi billion dollar market, multi billion dolar corporations and yet where are the products?

Really the arguments you present are ridiculous.

Have you been able to come up with any data in response from post 11264 and before. It is obvious that your data is seriously questionable at best and at worst.....

maybe yo umissed this. I left off the question mark.

Patent from 2004, yet where are the products? Multi billion dollar market, multi billion dolar corporations and yet where are the products?

Really the arguments you present are ridiculous.

Have you been able to come up with any data in response from post 11264 and before. It is obvious that your data is seriously questionable at best and at worst.....

Who is "we"?

I am finding the information you have provided to continually be lacking please note my earlier responses

Still waiting

as noted in post 11274 responding to your "facts". Waiting on a response to those items noted below

I am sorry but the continued incorrect information you have provided, without links and refuted with links and questions have put all of those "facts" in serious questions.

Even stating that "Just about everything in your post is inaccurate and/or irrelevant." in post 11264

is easily provable and the sources are simple and noted in post 11269

Just stating something is inaccurate does not make it so. I understand if the questions posted in post 11260 can be refuted because the "facts" were proven not to be so.

Here is my analysis of the patent for Eli 216. Everyone should read Elite's last argument and the accompanying basis for the arguments

One thing I missed in the post about the patent is that it is related to the extended release patent. Both are about the same polymer. Here is that analysis regarding the abuse resistant polymer used


Here is the key information

"The non-obviousness of a broader claimed range can be supported by evidence based on unexpected results from testing a narrower range if one of ordinary skill in the art would be able to determine a trend in the exemplified data which would allow the artisan to reasonably extend the probative value thereof. In re Kollman, 595 F.2d 48, 201 USPQ 193 (CCPA 1979) (Claims directed to mixtures of an herbicide known as "FENAC" with a diphenyl ether herbicide in certain relative proportions were rejected as prima facie obvious. Applicant presented evidence alleging unexpected results testing three species of diphenyl ether herbicides over limited relative proportion ranges.

The court held that the limited number of species exemplified did not provide an adequate basis for concluding that similar results would be obtained for the other diphenyl ether herbicides within the scope of the generic claims. Claims 6-8 recited a FENAC:diphenyl ether ratio of 1:1 to 4:1 for the three specific ethers tested. For two of the claimed ethers, unexpected results were demonstrated over a ratio of 16:1 to 2:1, and the effectiveness increased as the ratio approached the untested region of the claimed range. The court held these tests were commensurate in scope with the claims and supported the nonobviousness thereof.

However, for a third ether, data was only provided over the range of 1:1 to 2:1 where the effectiveness decreased to the "expected level" as it approached the untested region. This evidence was not sufficient to overcome the obviousness rejection.); "

So basically what this is saying and is the basis of Elite's claim of unobviousness is that while RS30 and NE30 behave the same over a certain range a person ordinary in the art would not expect the results that occurred in a more narrower range or beyond that range if you will just like the ratios noted above in the example.

As the ratio of polymer by weight is increased beyond a certain point, they begin to act much differently. And this is proved by the narrow range as tested and defined as 30%-50% of weight. The changes start at 30% and the Naltrexone is completely shut off at 50%

"The nonobviousness of a broader claimed range can be supported by evidence based on unexpected results from testing a narrower range if one of ordinary skill in the art would be able to determine a trend in the exemplified data which would allow the artisan to reasonably extend the probative value thereof."

Draw a line graph and the x axis going left to right is increase of polymer. The Y axis is permeability. The RS30 goes in a somewhat linear fashion Add more polymer get a somewhat predictable increase in permeability (ie sequesters the Naltrexone longer)

Then draw the NE30 line looking very similar to the RS30. However, once you hit a certain level of coating by weight of the pill, the NE30 begins to rise much more rapidly than the RS30.

At the point the NE30 is shutting down 100% of the Naltrexone, the RS30 is still leaking Naltrexone at 60 hours, That is just 2.5 days. You can't have this stuff leaking out in your body for many days. It is much more effective and results would not be known by one ordinary on the art.

So the argument is a very strong one which says that one in ordinary skill would be able to determine a trend. Note the two lines acting the same way for the first 24 hours.

"ordinary skill in the art would be able to determine a trend in the exemplified data which would allow the artisan to reasonably extend the probative value thereof"

However, because that trend is broken and the results become unexpected which the USPTO agrees with

"The nonobviousness of a broader claimed range can be supported by evidence based on unexpected results from testing a narrower range"

And Ph3, and works on all opioids!!!!!!!!

as noted in post 11274 responding to your "facts". Waiting on a response to those items noted below

I am sorry but the continued incorrect information you have provided, without links and refuted with links and questions have put all of those "facts" in serious questions.

Even stating that "Just about everything in your post is inaccurate and/or irrelevant." in post 11264

is easily provable and the sources are simple and noted in post 11269

Just stating something is inaccurate does not make it so. I understand if the questions posted in post 11260 can be refuted because the "facts" were proven not to be so.

Patent from 2004, yet where are the products. Multi billion dollar market, multi billion dolar corporations and yet where are the products?

Really the arguments you present are ridiculous.

Have you been able to come up with any data in response from post 11264 and before. It is obvious that your data is seriously questionable at best and at worst.....

". So, yes, until we can identify a funding source or at some point come up with our own capital to fund it, we are stuck"

However I have been trying to figure out what ype of companies or policies might be out there restricting 100% funding and only 50%.

My thoughts have ranged from Elite having a certain risk profile due to their current limited income, debt etc...

However, by making the deal with Socius, can they minimize that risk for a partner

Or

Is the Socius funding for Eli 154 directly?

I think there are a lot of big quantity share holders out there. The thing is the risk here is extremely minimal at this point. You know all the products that are coming out. You have a good shot at a true Homerun.

And remember is is not your typical OTC maybe they will, maybe they won't stay in business kind of thing. They have ~6 partners some of which are very big. And the connections between Actavis, Epic, MIkah, and Elite are extremely tight.

These guys have everything in their control except for timing by federal agencies. So for me it is just a matter of time. And as I noted, you know what is coming.

That sounds about right but I think the 10-20% is a bit low. You may know better then me but if Elite's margins were 40%, then that would mean that typically somewhere around costs of making the drug are only around 5% of revenue or something like a 90% profit margin.

Those are real rough numbers too. Not that important to me really. More revenue. Need to get to about 4-5m total per year as I see it for a full turn around. Old Lodrane gets us there but the three products are real nice.

26 or so more products to go

I did like what seemed like an updated company description

Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products, to improve off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry. Elite has four ANDA products partnered with TAGI Pharma; one ANDA has launched, two ANDAs are in the process of a manufacturing site transfer and an additional ANDA is currently under review by the FDA. Elite also manufactures Lodrane D® and receives royalties for Lodrane D®, an allergy product partnered with ECR Pharmaceuticals ("ECR"), a wholly owned subsidiary of Hi-Tech Pharmacal ("Hi-Tech"). Elite's lead pipeline products, ELI-216, a once-daily abuse resistant oxycodone, and ELI-154, a once-daily oxycodone, are novel sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also has partnered with Mikah Pharma to develop a new product and with Hi-Tech Pharmacal to develop an intermediate for a generic product. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.

straight contract manufacturing like Epic does. Also the packaging is healthy too.

They had a 500k settlement and then signed a new deal about a month later.

straight contract work plus they get paid for the packaging too

Again, without links, data, or "facts" or anything really to show how the items in 11264 are in fact inaccurate or irrelevant, I guess I disagree with that assessment. That is why linked data, provable facts, logic is so important.

So you are now agreeing that everything in post 11269 is as I noted, and the claim that

"Just about everything in your post is inaccurate and/or irrelevant."

from post 11264

was wrong

I am sorry but the continued incorrect information you have provided, without links and refuted with links and questions have put all of those "facts" in serious questions.

Even stating that "Just about everything in your post is inaccurate and/or irrelevant." in post 11264

is easily provable and the sources are simple and noted in post 11269

Just stating something is inaccurate does not make it so. I understand if the questions posted in post 11260 can be refuted because the "facts" were proven not to be so.

Its a great opportunity. Some would like to mislead to suit their own needs but it is important to verify all information. With this company it is easy since they are doing most everything right in front of you and give you enough information to understand what is going on.

Perhaps the two most telling things are

Who is going to benefit the most when the PPS rises?

Is there anything that is going to stop them?

With ~30 drugs they are poised to become a solid manufacturing company. They have 5-6 main partners how and these partners are depending on Elite to make these drugs. The FDA slows everything down but Elite will get there.

The ELi drugs are monsters though

Still waiting on links, answers, to all those items in post 11260

Copy pasting random things that are not relevant to those questions doesn't answer those questions

"Just about everything in your post is inaccurate and/or irrelevant."

Really?

Here they are and they are proven Facts and relevant


Updated: "Cui Bono" Who benefits - connect the dots

I wrote about this back in April during the strategic alliance which basically removed any threat of bankruptcy.

Epic owns half the board of directors and Epic execs are large shareholders themselves. Now, here is the simple part. If you were a board member with millions of shares, could pump as much money and products into Elite as you wanted to (We have seen this already with the 8 drugs, strategic alliance etc), what would your strategy be? (FACT and speculation based on FACT, it is what has transpired thus far)

Now also consider that Epic's president and CEO (Dr. Ashok Nigalaye,)is also........Elite's Chief Scientific Officer developing Eli 216. The one with the very strong patent response by Elite on 12/8 and the very same Elite has started up commercial batches. (FACT check the conf call)

Strategy is simple

To make as much money as possible. Elite has ~30 drugs in their pipeline right now that will be made at Elites facility. Elite just doubled their capacity. See the 8k where it is reconfirmed. Folks got a tour during the meeting and I am mad at myself for not going. (FACT - check the conf call, live tour, 10k, 8K, etc)

How many drugs does Epic have commercially? Per their website they have 10 - FACTS Check the website

Ok, how about the Pharma network? 15 per their website which is Ascend - FACTS Check the website

Ok, how about HITK? They have 90 but many are various forms of the same drug. They have about 20-30 actual drugs and a 400m market cap and are one of the fastest growing pharma companies per Forbes.
FACTS Check the website

Actavis is of course one of the largest generic companies in the world. (FACT -Multi-billion dollar global company)

Mikahs R&D is going to be made by Elite. It’s on their website. FACT

These are Elites partners (FACT)

What does Elite have that most of these companies don’t have? A DEA, FDA GMP facility. They make controlled substances and many are everyday common drugs, Phentermine a top diet drug, Hydromorphone which is Dilaudid, Methadone, Oxycontin, Lodrane,etc.. (FACT-check the companies websites)

And Mikahs products???? Percocet, Percodin etc. Check out the website. These are massive generic drugs. (Check website)

And who is Mikah? Designee of Actavis and consultant to the CEO of Epic. (FACT Conf call, 10K)

And I haven’t even mentioned the patents for unique and extremely valuable time release and abuse resistant drugs worth 100s of millions and really billions. BTW, Actavis makes Oxycontin too.
FACTs documented over and over

Of course we no have a partner willing to fund half of Eli 154 and we just need someone to fund the other half. A few million or so per the CEO on the last conf call..FACT

And what just happened to start the new year? We received 5m+ funding - FACT

“Cui Bono” Who benefits? The folks that own the stock, Epic, Mikah (owns a bunch), Elite of course.
FACT - PPS goes up, shareholders make money

Remember most of the shares in the increase in authorized shares or A/S is already spoken for by Epic. Warrants and Milestone shares. FACT 10K

So here is the kicker. While this would likely never happen except right before a merger, what would happen if Epic decided to convert and sell all those shares?They would drive the price below what they paid for them in the first place so that is not going to happen. FACT Basic Logic

The 8k was all about the above items. Things take time but with ~30 products to be made at Elite that we currently know about, this is just a matter of time in my opinion. SPECULATION BASED ON FACTS

Eli 216 is what I am referring

"Now also consider that Epic's president and CEO (Dr. Ashok Nigalaye,)is also........Elite's Chief Scientific Officer developing Eli 216. The one with the very strong patent response by Elite on 12/8 and the very same Elite has started up commercial batches. "

Elite's patent for Eli 216 was discussed on 12/8


You noted that you started doing DD a few days ago. This was from the conference call you listened to over the last few days, that occurred months ago. Do you have that link to the audio? Like I noted several times earlier in requesting this, it would be great if folks could listen for themselves and hear the excitement in mgmts responses.


I see that you have not been able to answer any of those questions or provide any of the links requested from information stated as supposed "fact". I am having doubts as to the sources of your information. Identified in post 11260.

Can you respond to those items?

As far as far as the Oshlock patent. That is exactly the point. Elite's tech is better and the results are not obvious. I realize you say that you have read thousands and thousands of pages, medical reports, charts and all the documentation that goes with every single patent on the subject, and all in a few days, but the information presented here continually defies what is actually written.

Guess I was correct again with actual relevant data and links noted:


From the conf call. Do you have the link for this as you noted that you listened to the conf call. Maybe you missed this part?

Jerry Treppel - Elite Pharmaceuticals, Inc. - Chairman of the Board, CEO
Well, remember, the fact that you manufactured a commercial-scale batch, that's nice, but after you do that, you have to analyze
it to make sure that it has the least characteristics that you want. Usually it takes a few tries before you get there. But, there's
no question we're moving the right direction. As you remember from the history of the Company, the scaling up of ELI-216 was
always (technical difficulty) in the development of the product.We think we have the right people now doing this who know
what they're doing.
Our CSO, Dr. Ashok Nigalaye, is an expert in controlled release, he knows what he's doing. So, we're confident that we're going
to get there and that's a big milestone for us, because if a product that you can make on the bench top is - it's almost like an
academic project, it doesn't mean a whole lot.You have to make it commercial quantities.What we're saying to you is really for
the first time in the Company's history, we're really moving towards that."

Updated: "Cui Bono" Who benefits - connect the dots

I wrote about this back in April during the strategic alliance which basically removed any threat of bankruptcy.

Epic owns half the board of directors and Epic execs are large shareholders themselves. Now, here is the simple part. If you were a board member with millions of shares, could pump as much money and products into Elite as you wanted to (We have seen this already with the 8 drugs, strategic alliance etc), what would your strategy be?

Now also consider that Epic's president and CEO (Dr. Ashok Nigalaye,)is also........Elite's Chief Scientific Officer developing Eli 216. The one with the very strong patent response by Elite on 12/8 and the very same Elite has started up commercial batches.

Strategy is simple

To make as much money as possible. Elite has ~30 drugs in their pipeline right now that will be made at Elites facility. Elite just doubled their capacity. See the 8k where it is reconfirmed. Folks got a tour during the meeting and I am mad at myself for not going.

How many drugs does Epic have commercially? Per their website they have 10

Ok, how about the Pharma network? 15 per their website which is Ascend

Ok, how about HITK? They have 90 but many are various forms of the same drug. They have about 20-30 actual drugs and a 400m market cap and are one of the fastest growing pharma companies per Forbes.

Actavis is of course one of the largest generic companies in the world.

Mikahs R&D is going to be made by Elite. It’s on their website.

These are Elites partners

What does Elite have that most of these companies don’t have? A DEA, FDA GMP facility. They make controlled substances and many are everyday common drugs, Phentermine a top diet drug, Hydromorphone which is Dilaudid, Methadone, Oxycontin, Lodrane,etc..

And Mikahs products???? Percocet, Percodin etc. Check out the website. These are massive generic drugs.

And who is Mikah? Designee of Actavis and consultant to the CEO of Epic.

And I haven’t even mentioned the patents for unique and extremely valuable time release and abuse resistant drugs worth 100s of millions and really billions. BTW, Actavis makes Oxycontin too.

Of course we no have a partner willing to fund half of Eli 154 and we just need someone to fund the other half. A few million or so per the CEO on the last conf call..

And what just happened to start the new year? We received 5m+ funding

“Cui Bono” Who benefits? The folks that own the stock, Epic, Mikah (owns a bunch), Elite of course.

Remember most of the shares in the increase in authorized shares or A/S is already spoken for by Epic. Warrants and Milestone shares.

So here is the kicker. While this would likely never happen except right before a merger, what would happen if Epic decided to convert and sell all those shares?They would drive the price below what they paid for them in the first place so that is not going to happen.

The 8k was all about the above items. Things take time but with ~30 products to be made at Elite that we currently know about, this is just a matter of time in my opinion.

Sorry but I was referring to all the other claims of fact that were actually discussed from post 11188-11223

Conference call link - can you provide that?

Analysis of the actual Patent in question

Claim of 3 years being a long time for a patent

If there are so many patents for this billion dollar market, held by billion dollar companies, how come where are the products?

Patent approvals not having an impact on stocks

The random copy pastes from the 10K did not provide any information in these regards

Actually most of the data you have provided has been proven to not be factual through actual linked data. The questions asked in regards to the claimed facts have gone unanswered. I question the source of those facts beyond random copy pasting of financial information from the 10K

Your post stated

"FACT: the "all important" Mehta patent has thus far been rejected, the company is still trying to argue its case "

But its not the Mehta patent

Once again, wrong, incorrect and misleading information

THE PATENT YOU POSTED IS NOT THE ELITE PATENT WE HAVE BEEN DISCUSSING. IN FACT IT IS NOT EVEN ELITES PATENT. LIKE I SAID THE FACTS PRESENTED ARE NOT FACTS AT ALL BUT INCORRECT AND IRRELEVANT.

LOL LOL

One thing I missed in the post about the patent is that it is related to the extended release patent. Both are about the same polymer. Here is that analysis regarding the abuse resistant polymer used


Here is the key information

"The nonobviousness of a broader claimed range can be supported by evidence based on unexpected results from testing a narrower range if one of ordinary skill in the art would be able to determine a trend in the exemplified data which would allow the artisan to reasonably extend the probative value thereof. In re Kollman, 595 F.2d 48, 201 USPQ 193 (CCPA 1979) (Claims directed to mixtures of an herbicide known as "FENAC" with a diphenyl ether herbicide in certain relative proportions were rejected as prima facie obvious. Applicant presented evidence alleging unexpected results testing three species of diphenyl ether herbicides over limited relative proportion ranges.

The court held that the limited number of species exemplified did not provide an adequate basis for concluding that similar results would be obtained for the other diphenyl ether herbicides within the scope of the generic claims. Claims 6-8 recited a FENAC:diphenyl ether ratio of 1:1 to 4:1 for the three specific ethers tested. For two of the claimed ethers, unexpected results were demonstrated over a ratio of 16:1 to 2:1, and the effectiveness increased as the ratio approached the untested region of the claimed range. The court held these tests were commensurate in scope with the claims and supported the nonobviousness thereof.

However, for a third ether, data was only provided over the range of 1:1 to 2:1 where the effectiveness decreased to the "expected level" as it approached the untested region. This evidence was not sufficient to overcome the obviousness rejection.); "

So basically what this is saying and is the basis of Elite's claim of unobviousness is that while RS30 and NE30 behave the same over a certain range a person ordinary in the art would not expect the results that occurred in a more narrower range or beyond that range if you will just like the ratios noted above in the example.

As the ratio of polymer by weight is increased beyond a certain point, they begin to act much differently. And this is proved by the narrow range as tested and defined as 30%-50% of weight. The changes start at 30% and the Naltrexone is completely shut off at 50%

"The nonobviousness of a broader claimed range can be supported by evidence based on unexpected results from testing a narrower range if one of ordinary skill in the art would be able to determine a trend in the exemplified data which would allow the artisan to reasonably extend the probative value thereof."

Draw a line graph and the x axis going left to right is increase of polymer. The Y axis is permeability. The RS30 goes in a somewhat linear fashion Add more polymer get a somewhat predictable increase in permeability (ie sequesters the Naltrexone longer)

Then draw the NE30 line looking very similar to the RS30. However, once you hit a certain level of coating by weight of the pill, the NE30 begins to rise much more rapidly than the RS30.

At the point the NE30 is shutting down 100% of the Naltrexone, the RS30 is still leaking Naltrexone at 60 hours, That is just 2.5 days. You can't have this stuff leaking out in your body for many days. It is much more effective and results would not be known by one ordinary on the art.

So the argument is a very strong one which says that one in ordinary skill would be able to determine a trend. Note the two lines acting the same way for the first 24 hours.

"ordinary skill in the art would be able to determine a trend in the exemplified data which would allow the artisan to reasonably extend the probative value thereof"

However, because that trend is broken and the results become unexpected which the USPTO agrees with

"The nonobviousness of a broader claimed range can be supported by evidence based on unexpected results from testing a narrower range"

FACTS:Most of the information posted is inaccurate and irrelevant

What is the point of copying and pasting random sections from the 10K and then the last patent info. I don't undertstand

I really don't undertand your point here. Looks like false, incorrect and irrelevant data

Wow copying the 10K. Like I asked what is your point? I don't get it. It's a 10K. We all read it months ago. They almost went bankrupt in 2008. Maybe you should post that too

What is your point?

Well what is your point?

And now we have funding for Eli 154.

1st quarter 2012

The patent argument description is below post# 11216

Methadone - I really believed we would see this launch by the end of the year but it didn't. We know they are working on it so it is any day now. Hopefully this upcoming week.

Hydromorphone and Naltrexone - FDA Pre-approval inspections completed in August I believe. That was almost 5 months ago. We should see this launch this quarter.

Additional ANDA approved and launched - Also part of the FDA pre-approval inspections in August. I really want to know what drug this is.

Lodrane 24, 24D - I am guessing 50/50 on these coming back this quarter. ECR and Hi-Tech (HITK) have been working on this since 2010. The petition in court was originally asking for a delay until 1st quarter as well for manufacturing so it would seem they saw this as the timeline for approval as an NDA

Patent news - This company has been trying to get these patents through for years. The abuse resistant patent is very very close. I encourage everyone to read the latest submission to the USPTO. Note that this came after they had a conference call with the office regarding the also close extended release patent. Elite has clearly demonstrated that the results of their tech are not only not obvious but actually contrary to the results someone in the art would expect. The patent office agrees with this and Elite has provided the evidence to support it. Patent 12/478,952

The extended release patent is also close. Also note that the tech in the abuse resistant may also provide IP coverage for the extended release patent. 10/951,978 My understanding is that Elite has to narrow the scope of the claim to either be only about Oxy where they can demonstrate with data that the results are not obvious and in fact unexpected or they remove the 40% claim since each opioid would have it's own profile

1st Epic drug will probably go out this quarter as well. The company has alluded to this fact. I also expected this to launch in 2011

Actavis drugs - We should get some news on the launch timeframe on these. Isradipine is the one to watch. 50m market with few competitors.


The most telling piece of data from the company is that they have started commercial batches of Eli 216. Based on discussions with IR as some here have confirmed there are basically 2 reasons to do this. Ramping up for PH3 or demonstrating to a partner that your tech works (no leakage of the Naltrexone)....or both

Note that Elite has an SPA from the FDA and they are likely to perform added trials to show efficacy results with food and folks with sensitive stomachs and such. The tech works.

Bottom line for me as it always has. Show me another company that has this pipeline and this massive potential and is already at PH3 trials for an 800m drug you know has a very likely chance to be approved as it is using existing approved medicines.

This is just 1st quarter and we could also see something on HITKs 100m intermediate or some of the other drugs in the pipeline.

Sure. Do take a look at what I wrote about the patent arguments by Elite and "obviousness". That is actually very interesting and relevant. Post 11216

That is worth discussing